Difurunsi Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 4

Difurunsi General Information

Description

Developer of recombinant virus technology designed for vaccine research and antiviral drug evaluation. The company utilizes a modular design-construct-verify-learn approach to perform targeted editing of viral vectors for genetic engineering, providing pharmaceutical companies with protease inhibitor screening systems, hpv pseudoviruses, inactivated virus products, live attenuated vaccines, oncolytic virus platforms and recombinant viral vectors to validate drug candidates within cellular microenvironments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 601, 6th Floor, Building C
  • Number 688 Bin'an Road, Changhe Street, Binjiang District
  • Hangzhou, Zhejiang 310052
  • China
+86 0571
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Vertical(s)
Corporate Office
  • Room 601, 6th Floor, Building C
  • Number 688 Bin'an Road, Changhe Street, Binjiang District
  • Hangzhou, Zhejiang 310052
  • China
+86 0571

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Difurunsi Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private 08-Jul-2026 Completed Generating Revenue
5. Later Stage VC 17-Jun-2025 Completed Generating Revenue
4. Later Stage VC (Series A) 17-Dec-2022 Completed Generating Revenue
3. Secondary Transaction - Private 01-Dec-2021 Completed Generating Revenue
2. Early Stage VC 01-Apr-2021 Completed Generating Revenue
1. Early Stage VC 29-Apr-2020 Completed Generating Revenue
To view Difurunsi’s complete valuation and funding history, request access »

Difurunsi Patents

Difurunsi Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-1446789-A Production of benzenesulphonamides Inactive 27-Nov-1973
GB-1445257-A Preparation Inactive 04-Oct-1973
GB-1441352-A Preparation of a benzamide Inactive 17-Sep-1973
GB-1439295-A Hydroxylamine derivative and its preparation and conversion to n- diethylaminoethyl- 2 - methoxy - 5-methylsulphonylbenzamide Inactive 10-Sep-1973
GB-1455595-A Preparation of 2,5-disubstituted benzamides Inactive 12-Apr-1973 C07D207/09
To view Difurunsi’s complete patent history, request access »

Difurunsi Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hefei Industry Investment Group Venture Capital Minority
Hangzhou Hi-Tech Financial Investment Group Venture Capital Minority
Hangzhou Tianhe Hi-Tech Accelerator/Incubator Minority
Shulan Junjie Capital Venture Capital Minority
To view Difurunsi’s complete investors history, request access »

Difurunsi FAQs

  • When was Difurunsi founded?

    Difurunsi was founded in 2017.

  • Where is Difurunsi headquartered?

    Difurunsi is headquartered in Hangzhou, China.

  • What industry is Difurunsi in?

    Difurunsi’s primary industry is Biotechnology.

  • Is Difurunsi a private or public company?

    Difurunsi is a Private company.

  • What is Difurunsi’s current revenue?

    The current revenue for Difurunsi is .

  • Who are Difurunsi’s investors?

    Hefei Industry Investment Group, Hangzhou Hi-Tech Financial Investment Group, Hangzhou Tianhe Hi-Tech, and Shulan Junjie Capital have invested in Difurunsi.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process